{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:41:31Z","timestamp":1770817291513,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.dld.2021.11.009","type":"journal-article","created":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T20:47:57Z","timestamp":1638823677000},"page":"192-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in Israel"],"prefix":"10.1016","volume":"54","author":[{"given":"Irit","family":"Avni-Biron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariella","family":"Bar-Gil Shitrit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Koslowsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asaf","family":"Levartovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uri","family":"Kopylov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roni","family":"Weisshof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathaniel","family":"Aviv Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitsan","family":"Maharshak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hovel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eran","family":"Israeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timna","family":"Naftali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Idan","family":"Goren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yfat","family":"Snir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob E.","family":"Ollech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagar","family":"Banai-Eran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yelena","family":"Broitman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tali","family":"Sharar-Fischler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Dotan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henit","family":"Yanai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.dld.2021.11.009_bib0001","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMra1102942","article-title":"Ulcerative Colitis","volume":"365","author":"Danese","year":"2011","journal-title":"N Engl J Med"},{"issue":"9853","key":"10.1016\/j.dld.2021.11.009_bib0002","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(12)60150-0","volume":"380","author":"Ord\u00e1s","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2021.11.009_bib0003","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2021.11.009_bib0004","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2021.11.009_bib0005","doi-asserted-by":"crossref","DOI":"10.1002\/ibd.21697","article-title":"Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies","author":"Reinisch","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2021.11.009_bib0006","article-title":"Long-term efficacy of vedolizumab for ulcerative colitis","author":"Loftus","year":"2017","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.dld.2021.11.009_bib0007","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2021.11.009_bib0008","doi-asserted-by":"crossref","DOI":"10.1185\/03007995.2016.1168290","article-title":"Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States","author":"Sandborn","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.dld.2021.11.009_bib0009","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.11.009_bib0010","doi-asserted-by":"crossref","DOI":"10.1159\/000496739","article-title":"Unmet Medical Needs in Ulcerative Colitis: an Expert Group Consensus","author":"Danese","year":"2019","journal-title":"Dig Dis"},{"key":"10.1016\/j.dld.2021.11.009_bib0011","doi-asserted-by":"crossref","DOI":"10.1177\/1756284819848631","article-title":"Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience","author":"D'Amico","year":"2019","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.dld.2021.11.009_bib0012","doi-asserted-by":"crossref","DOI":"10.2217\/imt-2015-0031","article-title":"Tofacitinib in ulcerative colitis","author":"Archer","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.dld.2021.11.009_bib0013","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2021.11.009_bib0014","unstructured":"Safety trial finds risk of blood clots in the lungs and death with higher dose of tofacitinib (Xeljanz, Xeljanz XR) in rheumatoid arthritis patients; FDA to investigate. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/safety-trial-finds-risk-blood-clots-lungs-and-death-higher-dose-tofacitinib-xeljanz-xeljanz-xr"},{"key":"10.1016\/j.dld.2021.11.009_bib0015","unstructured":"FDA. FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR). https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and"},{"key":"10.1016\/j.dld.2021.11.009_bib0016","unstructured":"EMA. EMA confirms Xeljanz to be used with caution in patients at high risk of blood clots. Published online 2019. https:\/\/www.ema.europa.eu\/en\/news\/ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots"},{"key":"10.1016\/j.dld.2021.11.009_bib0017","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis","author":"Magro","year":"2017","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.dld.2021.11.009_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.dld.2019.10.003","article-title":"Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis","author":"Lair-Mehiri","year":"2020","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2021.11.009_bib0019","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaa075","article-title":"Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: a Multicentre UK Experience","author":"Honap","year":"2020","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.dld.2021.11.009_bib0020","doi-asserted-by":"crossref","DOI":"10.1097\/MEG.0000000000002028","article-title":"Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis","author":"Straatmijer","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.11.009_bib0021","article-title":"Tofacitinib in Ulcerative Colitis: real-world Evidence From the ENEIDA Registry","author":"Chaparro","year":"2020","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.dld.2021.11.009_bib0022","doi-asserted-by":"crossref","DOI":"10.1007\/s10620-019-05492-y","article-title":"Real-World Experience with Tofacitinib in IBD at a Tertiary Center","author":"Weisshof","year":"2019","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2021.11.009_bib0023","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9072177","article-title":"Tofacitinib in Treatment-Refractory Moderate to Severe Ulcerative Colitis: real-World Experience from a Retrospective Multicenter Observational Study","author":"Hoffmann","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.dld.2021.11.009_bib0024","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjz119","article-title":"DOP58 tofacitinib for ulcerative colitis: results of the ICC Registry, a nationwide prospective observational cohort study","author":"Biemans","year":"2020","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.dld.2021.11.009_bib0025","article-title":"Tofacitinib in ulcerative colitis: real-world evidence from the ENEIDA registry","author":"Chaparro","year":"2021","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.dld.2021.11.009_bib0026","article-title":"796 \u2013 Real-World Effectiveness of Tofacitinib in Ulcerative Colitis; a Multi-Center Study","author":"Patel","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.11.009_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(20)33679-9","article-title":"Tu1892 TOFACITINIB FOR ULCERATIVE COLITIS: RESULTS OF THE ICC REGISTRY, A NATIONWIDE PROSPECTIVE OBSERVATIONAL COHORT STUDY","author":"Biemans","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.11.009_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2020.01.008","article-title":"First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: an Updated Network Meta-Analysis","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.11.009_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2018.11.035","article-title":"Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials","author":"Sandborn","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.11.009_bib0030","doi-asserted-by":"crossref","DOI":"10.14309\/01.ajg.0000592440.22488.10","article-title":"726 Tofacitinib for the Treatment of Ulcerative Colitis: analysis of Infection Rates in the Tofacitinib Ulcerative Colitis Clinical Program","author":"Winthrop","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2021.11.009_bib0031","article-title":"Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis","author":"Deepak","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.11.009_bib0032","article-title":"Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: systematic Review With Meta-Analysis","author":"Taxonera","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2021.11.009_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2019.04.059","article-title":"Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis","author":"Sands","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.11.009_bib0034","unstructured":"EMA. Xeljanz (tofacitinib): initial clinical trial results of increased risk of major adverse cardiovascular events and malignancies (excluding NMSC) with use of tofacitinib relative to TNF\u2014 Alpha inhibitors. Published online 2021. doi: EMA\/154969\/2021"},{"key":"10.1016\/j.dld.2021.11.009_bib0035","article-title":"Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status","author":"Sandborn","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.11.009_bib0036","article-title":"Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial","author":"Vermeire","year":"2020","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.dld.2021.11.009_bib0037","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining Therapeutic Goals for Treat-to-Target strategies in IBD","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.11.009_bib0038","article-title":"Mucosal healing in ulcerative colitis - when zero is better","author":"Carvalho","year":"2016","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.dld.2021.11.009_bib0039","doi-asserted-by":"crossref","DOI":"10.1080\/14712598.2020.1701652","article-title":"Histological healing: should it be considered as a new outcome for ulcerative colitis?","author":"Dal Buono","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.dld.2021.11.009_bib0040","unstructured":"EMA. Guideline on the development of new medicinal products for the treatment of Ulcerative Colitis. Published online 2018. doi:28 June 2018 CHMP\/EWP\/18463\/2006 Rev.1 Committee for Medicinal Products for Human Use (CHMP)"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865821008495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865821008495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:17:20Z","timestamp":1761625040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865821008495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1590865821008495"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2021.11.009","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in Israel","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2021.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}